AlloNK + Obinutuzumab
Systemic Lupus Erythematosus, Lupus Nephritis
Phase 1/2Active
Key Facts
Indication
Systemic Lupus Erythematosus, Lupus Nephritis
Phase
Phase 1/2
Status
Active
Company
About Artiva Biotherapeutics
Artiva Biotherapeutics is advancing a scalable, allogeneic NK cell therapy platform to overcome the toxicity, cost, and manufacturing limitations of current cell therapies. Its lead program, AlloNK, is in multiple Phase 1/2 trials for autoimmune diseases and B-cell malignancies, leveraging a unique combination approach with monoclonal antibodies. The company's strategy is built on a manufacturing-first approach, enabled by a strategic partnership with GC Cell, aiming to deliver safe, effective, and accessible treatments.
View full company profile